Login to Your Account

Will Nanobody be Son of Humira?

Abbvie Helps Ablynx ‘Grow Up’ with $840M

By Nuala Moran
Staff Writer

Monday, September 23, 2013
LONDON – Ablynx NV signed an $840 million licensing deal with Abbvie Inc. for its ALX-0061 nanobody targeted against the cytokine interleukin-6 receptor (IL-6R), in the treatment of rheumatoid arthritis and systemic lupus erythematosus.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription